HCN Tissue Bank: Tissue/Body Fluid Procurement and Clinical Data Collection for Patients with Malignancies of the Head and Neck Area and/or Pre-Malignant Changes
Aims: The purpose of this study is to collect tissue, blood, saliva, and/or clinical data (information about your treatment) from patients with a cancer in the head and neck area (or pre-malignant lesions) for research purposes. Certain genetic and biochemical changes are believed to lead to the development of head and neck cancer. Scientists are attempting to discover and understand the function of these changes. In the future, improved understanding of these changes may help us to better detect head and neck cancers and offer improved treatments.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH13-276
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

RTOG-1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell cancer of the Head and Neck
Aims: The purpose of the this part of this study is to find out what effects, good and/or bad, one of the following treatments has on you and your cancer. In this part of the study, you will receive one of the following treatments:

  • Standard treatment: radiation therapy and cisplatin
  • Experimental treatment: radiation therapy and docetaxel
  • Experimental treatment: radiation therapy, docetaxel, and cetuximab

Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-004
Sponsor: Radiation Therapy Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

A091101: Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib)- a Randomized Phase 1 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Aims: The purpose of the study is to find the highest safe dose of the investigational drug, ABT-888 when combined with chemotherapy.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-353
Sponsor: Alliance
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes